HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ross, A. P. Search for Related Content PubMed PubMed Citation Articles by Ross, A. P.

Tolerability, adherence, and patient outcomes

From the Department of Neurosciences, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois.

Address correspondence and reprint requests to Ms. Amy Perrin Ross, Loyola University Chicago, Stritch School of Medicine, 2160 S. First Ave., Maywood, IL 60153 aperrin{at}lumc.edu

Providing optimal patient care in multiple sclerosis (MS) is dependent on both the patient and the healthcare system. One of the greatest challenges to optimal patient care is ensuring patient adherence to treatment. The two reasons given most often for treatment discontinuation are adverse effects and lack of efficacy. Adverse effects can be anticipated and managed, in part through well-established protocols, but also through industry-sponsored nursing support programs. These strategies can reduce needless discontinuations when patients experience common adverse effects. Lack of efficacy can be addressed for many patients by providing them with enough education to develop reasonable expectations for treatment and long-term prognosis. As important as early and continuous treatment are, these strategies are essential for providing optimal patient care in MS.

Disclosure: Consulting Agreements: Bayer HealthCare Pharmaceuticals; EMD Serono, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corp; Pfizer Inc; Teva Neuroscience, Inc. Speakers’ Bureau/Honorarium Agreements: Bayer HealthCare Pharmaceuticals; EMD Serono, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corp; Pfizer Inc; Teva Neuroscience, Inc.

Neurology® supplements are not peer-reviewed. Information contained in Neurology® supplements represents the opinions of the authors. These opinions are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology®.